Follow the links to see the 2 abstracts. Looks promising. When Oncoceutics had their webinar with us last week, they told me about the results but were not allowed to disclose them publicly until these abstracts were published.. so here they are!
These last 2 webinars are each focused on an individual treatment:
Tonight: Tocagen - this is an experimental gene therapy. Absolutely fascinating. Dr Gruber will explain how it works and how it can kill cancer cells without hurting the normal cells.
Next Sunday: Gamma Tiles. This is an FDA "cleared" product - which means it is available now. Very few people know about it yet. This is a device that is implanted at the time of surgery into the cavity remaining after surgical removal of the tumor. It delivers radiation therapy to the tumor bed so it stops those cells from dividing.
So sad to hear of another clinical trial failure of a gbm drug. They did not release the details yetso we do not know if it is worth trying it in some other way or in combinations with other drugs yet.
These meetings are for anyone who uses or is thinking of using Optune. Most of these are live but there are some broadcast on the web!
Our new edition is finally available! Please let me know what you think of it. Every chapter has been updated and we added about 15 pages.
This would be a huge breakthrough if it works. I love research like this and wish them well.
The first 2 webinars in the series went very well and you can view them at virtualtrials.com/video.cfm
There are many ways to use the checkpoint inhibitors. This study shows that using Opdivo instead of Temodar during radiation for newly diagnosed is not helping. This doesn't mean the drug is bad - just that it isn't being used correctly. There are other trials going on that hopefully will show us how best to use this class of drug!
The new edition will arrive sometime this week!
We need to fight this. I will provide details next week!
We have one this Sunday and Wednesday! Both have excellent speakers. Sunday is on Immunotherapies, Wednesday is on Onc-201 for DIPG and H3K27M mutant gliomas.
This is very early but it is an exciting new type of treatment for dipg. The Musella Foundation is part of the DIPG Collaborative and helped fund this project!
This may be the missing link in understanding how the immune system fights cancer and why checkpoint inhibitors do not allwas work. Excellent research and I hope someone tests this in brain tumors.
From our good friends at the End Brain Cancer Initiative, Should be interesting.
This is exciting for the drug Onc-201. The meeting is not for approval but for the FDA to learn about the drug and help guide the process to approval. This is not done for most drugs.
Dr Ashley will be speaking about immunotherapies and specifically the Polio Vaccine and CMV vaccines at Duke!
There is a desperate need for this. I wish them luck and will be watching closely. Dr Okada is on our medical advisory board and is one of the world experts on this topic.
We added another webinar to our lineup:
5/15/2019: WEDNESDAY Topic: Onc-201 for DIPG and H3K27M mutant gliomas!
I am a fan of the CUSP 9 protocol. Might be worth considering adding it to whatever else your plan is.
Here is an updated list of the Optune Open Houses. These meetings are interesting and a lot of fun for everyone who has a brain tumor.